BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29341150)

  • 1. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
    Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
    Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer.
    Pucci S; Polidoro C; Joubert A; Mastrangeli F; Tolu B; Benassi M; Fiaschetti V; Greco L; Miceli R; Floris R; Novelli G; Orlandi A; Santoni R
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):381-388. PubMed ID: 28068245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
    Tian YF; Chen TJ; Lin CY; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Shiue YL; Huang HY; Pan HY; Li CF; Chen SH
    Tumour Biol; 2013 Apr; 34(2):1107-17. PubMed ID: 23328995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
    Sloothaak DA; Geijsen DE; van Leersum NJ; Punt CJ; Buskens CJ; Bemelman WA; Tanis PJ;
    Br J Surg; 2013 Jun; 100(7):933-9. PubMed ID: 23536485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors].
    Wang XJ; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
    Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):419-423. PubMed ID: 27938574
    [No Abstract]   [Full Text] [Related]  

  • 7. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.
    Farkas R; Pozsgai E; Schally AV; Szigeti A; Szigeti E; Laszlo Z; Papp A; Gomori E; Mangel L; Horvath PO; Bellyei S
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):387-95. PubMed ID: 22160161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
    McCoy MJ; Hemmings C; Anyaegbu CC; Austin SJ; Lee-Pullen TF; Miller TJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
    Oncotarget; 2017 Mar; 8(12):19803-19813. PubMed ID: 28177891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Mucin Proportion in the Pretreatment MRI on the Outcomes of Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
    Kim E; Kim K; Kim SH; Han SW; Kim TY; Jeong SY; Park KJ; Koh J; Kang GH; Chie EK
    Cancer Res Treat; 2019 Jul; 51(3):1188-1197. PubMed ID: 30590006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
    Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.
    Seierstad T; Hole KH; Grøholt KK; Dueland S; Ree AH; Flatmark K; Redalen KR
    Br J Radiol; 2015 Jul; 88(1051):20150097. PubMed ID: 25899892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of gene biomarkers to predict responses to neoadjuvant chemoradiotherapy in patients with rectal cancer and pathways enrichment analysis].
    Wang XJ; Yu Q; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1183-1187. PubMed ID: 31874536
    [No Abstract]   [Full Text] [Related]  

  • 16. BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.
    Flanagan L; Lindner AU; de Chaumont C; Kehoe J; Fay J; Bacon O; Toomey S; Huber HJ; Hennessy BT; Kay EW; McNamara DA; Prehn JH
    J Mol Med (Berl); 2015 Mar; 93(3):315-26. PubMed ID: 25388617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy.
    Iannicelli E; Di Pietropaolo M; Pilozzi E; Osti MF; Valentino M; Masoni L; Ferri M
    Abdom Radiol (NY); 2016 Oct; 41(10):1906-17. PubMed ID: 27323759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
    Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.